CABAZITAXEL

SynDRA canonical compound SYN0023601 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	CYP2C8 \| CYP3A5 \| SLCO1B3 \| TUBA1A \| TUBA1B \| TUBA1C \| TUBA3C \| TUBA3D \| TUBA3E \| TUBA4A \| TUBB \| TUBB1 \| TUBB2A \| TUBB2B \| TUBB3 \| TUBB4A \| TUBB4B \| TUBB6 \| TUBB8
Mechanism of action	microtubule inhibitor
Indication	prostate cancer
Disease area	oncology

All known targets

jevtana
RPR-116258A
XRP-6258
cabazitaxel acetonate
cabazitaxel acetone
javtana
Cabazitaxel acetonate
Jevtana
NSC-761432
TXD-258
TXD258
XRP6258
Cabazitaxel accord
Jevtana kit
Taxoid XRP6258
Jevtana (TN)
XRP 6258
Cabazitaxelum
Xrp6258
NSC 761432
CHEBI:63584
51F690397J
kabazitaxel
Jevtana Kit
Cabazitaxel (Jevtana)
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate.
CABAZITAXEL ACETONATE [JAN]
Cabazitaxel Injection
Cabazitaxel [USAN:INN]
Jevanta
UNII-51F690397J
CABAZITAXEL [MI]
CABAZITAXEL [INN]
Cabazitaxel (USAN/INN)
CABAZITAXEL [USAN]
CABAZITAXEL [VANDF]